Dr. Martin Pfister

Principal / Authorized Signatory

Dr. Martin Pfister studied medicine and pharmacy at the University of Greifswald and New York University and received his doctorate in immunology. He worked in various academic laboratories. Since 2000 he has been active in the start-up scene. He took over management positions and is co-founder of two successful companies in the fields of diagnostics & health services. In 2010 he transferred to the HTGF on the investor side. With his long-standing experience in drug development/gene therapy and medical technology/diagnostics, he is a valued sparring partner for portfolio companies in the fields of biotechnology and healthcare. He also holds several advisory board positions with portfolio companies.

Portfolio

Exit

Teilexit

Exit

Posts & mentions

Press

16. March 2023

Successful exit for HTGF: Miltenyi Biotec acquires biosensor company lino Biotech

Zurich, March 16, 2023 - lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography®, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses i

Blog

5. October 2021

Life Science Pitch Day: Real entrepreneurs, real innovation, real added value

It was a special moment when CureVac founder Ingmar Hoerr shared his business story at the Life Science Pitch Day. More than 30 start-ups, investors, and scientists took part in the event at the end of September, which was organised by High-Tech Gründerfonds (HTGF) together with partners Bayer, Boehringer Ingelheim and the Innovation and Start-Up Center Biotechnology (IZB). We spoke to the event organisers at HTGF: Dr. Caroline Fichtner and Dr. Martin Pfister, both HTGF Principals, touched